Sevelamer reduces endothelial inflammatory response to advanced glycation end products

BACKGROUND: Advanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum in vitro and then test this pharmace...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Kidney J
Autores principales: Gregório, Paulo C, Favretto, Giane, Sassaki, Guilherme L, Cunha, Regiane S, Becker-Finco, Alessandra, Pecoits-Filho, Roberto, Souza, Wesley M, Barreto, Fellype C, Stinghen, Andréa E M
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
CKD Complications
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5798142/
https://ncbi.nlm.nih.gov/pubmed/29423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfx074
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares